FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * $\underline{MacLean\ Michael\ F}$							2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]								5. Relationship of Reporting Person(s) to Issu (Check all applicable) Director 10% Owr				
(Last) (First) (Middle) 14 CAMBRIDGE CENTER							3. Date of Earliest Transaction (Month/Day/Year) 11/01/2007								Officer (give title below) SVP, Chief According		Other (s below) ing Office	·	
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - No	n-Deri\	ative	e Sec	uriti	ies Ac	quired	, Dis	posed o	of, or Be	neficia	lly Owne	d				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ar) E	P.A. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Benefic Owned	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			Instr. 4)	
Common Stock 11/01/2						2007		М		1,000	A	\$0.0	0 20,26	20,265.0454(1)		D			
Common Stock 11/01/2						2007		F		318	D	\$72.	37 19,94	47.0454		D			
		7	able II -								osed of converti			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,		Transaction Code (Instr.		n of		xercis n Date ay/Ye			f s g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owi Fori Dire or li (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Unit	\$0.00	11/01/2007			M			1,000	11/01/20	07	11/01/2007	Common Stock	1,000	\$0.00	2,000		D		

Explanation of Responses:

1. Includes 30.2018 shares acquired under the Biogen Idec Inc. employee stock purchase plan on 9/28/2007.

Remarks:

Robert A. Licht, Attorney in fact for Michael F. Maclean

11/02/2007

** Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly.$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).